← Human Trials & Peer-Reviewed Studies
Design of the RELAXin in acute heart failure study
Plain-language guide to PMID 22305830 (2012): double-blind randomized controlled trial study of Relaxin (Serelaxin) in 2011, patients.
Key Facts
- PMID
- 22305830
- Journal
- American heart journal
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Ponikowski P et al. (13 authors)
- DOI
- 10.1016/j.ahj.2011.10.009
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Relaxin (Serelaxin), published as a randomized controlled trial.
Acute heart failure (AHF) remains a major public health burden with a high prevalence and poor prognosis.
The RELAX-AHF-1 study will evaluate the effect of RLX030 (recombinant form of human relaxin 2) on symptom relief and clinical outcomes in patients with AHF.
Who Took Part
The abstract describes 2011, patients taking part.
PubMed tags the participants as both men and women.
Patients with AHF and systolic blood pressure >125 mm Hg are randomized within 16 hours of presentation to a 48-hour IV infusion of RLX030 or placebo.
Patients will be followed up through day 180 for mortality.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Relaxin (Serelaxin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the patients nor the staff measuring them knew who was on Relaxin (Serelaxin), so expectations could not easily colour the readings.
Some patients received a placebo instead of Relaxin (Serelaxin), giving a reference point.
As of September 19, 2011, 978 patients have been enrolled.
What Was Measured
The RELAX-AHF-1 study will evaluate the effect of RLX030 (recombinant form of human relaxin 2) on symptom relief and clinical outcomes in patients with AHF.
The subject headings attached to it are Acute Disease, Blood Pressure, Europe, Heart Failure, Length of Stay, Recombinant Proteins and Relaxin.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Relaxin (Serelaxin) in 2011, patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2012 (American heart journal), a journal based in United States.
More context: the Relaxin (Serelaxin) compound page, all human trials.
Our Notes on the Compound
Relaxin (Serelaxin): A pregnancy hormone that relaxes blood vessels; serelaxin is a recombinant form studied in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.